IL183307A0 - Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists - Google Patents

Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists

Info

Publication number
IL183307A0
IL183307A0 IL183307A IL18330707A IL183307A0 IL 183307 A0 IL183307 A0 IL 183307A0 IL 183307 A IL183307 A IL 183307A IL 18330707 A IL18330707 A IL 18330707A IL 183307 A0 IL183307 A0 IL 183307A0
Authority
IL
Israel
Prior art keywords
hif
adenosine
cancer
receptor antagonists
mediated disorders
Prior art date
Application number
IL183307A
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of IL183307A0 publication Critical patent/IL183307A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL183307A 2004-11-22 2007-05-17 Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists IL183307A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055704P 2004-11-22 2004-11-22
PCT/US2005/042551 WO2007040565A2 (en) 2004-11-22 2005-11-22 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists

Publications (1)

Publication Number Publication Date
IL183307A0 true IL183307A0 (en) 2008-04-13

Family

ID=37906593

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183307A IL183307A0 (en) 2004-11-22 2007-05-17 Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists

Country Status (6)

Country Link
EP (1) EP1827445A2 (en)
JP (1) JP2008520746A (en)
AU (1) AU2005336924A1 (en)
CA (1) CA2586420A1 (en)
IL (1) IL183307A0 (en)
WO (1) WO2007040565A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2318649T3 (en) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS.
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
CN101337930B (en) 2003-11-11 2010-09-08 卫材R&D管理有限公司 Urea derivative preparation process
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (en) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
WO2009060945A1 (en) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
WO2010054763A1 (en) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclically substituted aryl compounds as hif inhibitors
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
CN104755463A (en) 2012-12-21 2015-07-01 卫材R&D管理有限公司 Amorphous form of quinoline derivative, and method for producing same
WO2014153363A1 (en) * 2013-03-18 2014-09-25 Northeastern University Method for generation of broadly neutralizing anti-pathogen antibodies
MX368099B (en) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
JO3783B1 (en) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd Highly pure quinoline derivative and method for producing the same
DK3263106T3 (en) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107801379B (en) 2015-06-16 2021-05-25 卫材R&D管理有限公司 Anticancer agent
WO2021028382A1 (en) * 2019-08-12 2021-02-18 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114574580B (en) * 2022-02-14 2022-11-29 山东大学 Application of targeted A2BR combined chemotherapy in treatment of triple negative breast cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
CA2586420A1 (en) 2007-04-12
WO2007040565A3 (en) 2009-04-16
JP2008520746A (en) 2008-06-19
EP1827445A2 (en) 2007-09-05
AU2005336924A1 (en) 2007-04-12
WO2007040565A9 (en) 2007-07-05
WO2007040565A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
IL183307A0 (en) Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists
IL183310A0 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
HK1210495A1 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
ZA200709922B (en) Novel MCHR1 antagonists and their use for the treatment of MCHR1 mediated conditions and disorders
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1929291A4 (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
IL184371A0 (en) Methods of treating skin disorders using an il-31ra antagonist
EP1926521A4 (en) Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
EP1827391A4 (en) Dosage forms and methods of use thereof
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL214198A0 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
PL1890684T3 (en) Treatment of sleep-wake disorders
EP1740172A4 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
IL181706A0 (en) The treatment of inflammatory disorders and pain
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
HK1127608A1 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
PL1751175T3 (en) Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1833991A4 (en) Trefoil factors and methods of treating proliferation disorders using same
EP1812009A4 (en) Gaba-steroid antagonists and their use for the treatment of cns disorders
EP1732599A4 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
EP1819346A4 (en) Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases
SI1644351T1 (en) Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL182768A (en) Combination comprising fluoxetine and the glucocorticoid receptor antagonist ru34850 for use in the treatment of depression or a related disorder